Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Is the FDA regulation of cardiology AI devices supporting cardiovascular innovation: a scoping review
2
Zitationen
8
Autoren
2025
Jahr
Abstract
While AI/ML technologies are reshaping cardiology, regulatory challenges and reporting transparency impede their optimal use. Strengthened regulatory frameworks, improved trial design and robust post-market surveillance are essential to ensure safety, efficacy and equity in the deployment of AI tools in cardiology.
Ähnliche Arbeiten
Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI
2019 · 8.551 Zit.
Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead
2019 · 8.443 Zit.
High-performance medicine: the convergence of human and artificial intelligence
2018 · 7.942 Zit.
BioBERT: a pre-trained biomedical language representation model for biomedical text mining
2019 · 6.792 Zit.
Proceedings of the 19th International Joint Conference on Artificial Intelligence
2005 · 5.781 Zit.